Stereotaxis, Inc.
About Stereotaxis, Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $32.4M
- Net income
- -$21.6M
- Total assets
- $52.3M
- Market cap
- $174.0M
- Gross margin
- 52.7%
- Operating margin
- -68.3%
- Net margin
- -66.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $32.4M
- Cost of revenue
- $15.3M
- Gross profit
- $17.1M
- Operating expenses
- $39.2M
- Operating income
- -$22.1M
- Income tax
- $2.2M
- Net income
- -$21.6M
- EPS (basic)
- $-0.25
- EPS (diluted)
- $-0.25
Balance sheet
- Total assets
- $52.3M
- Current assets
- $33.8M
- Total liabilities
- $33.5M
- Current liabilities
- $22.4M
- Shareholders’ equity
- $13.5M
Cash flow
- Operating cash flow
- -$13.7M
- Investing cash flow
- -$93.0K
- Financing cash flow
- $14.8M
- Net cash flow
- $985.0K
Statements via Polygon.io (SEC filings)
- Market cap
- $174.0M
- EPS (diluted)
- $-0.25
- Shares outstanding
- 96.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 12, 2004
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $21.6M in FY2025.
- Revenue declined 8% from FY2021 to FY2025.
- Gross margin of 52.7%, net margin -66.8%.
- Trading 49% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Stereotaxis, Inc..
Write a review
News about Stereotaxis, Inc.
News & sentiment via Polygon.io
